A 2020 Spanish study found CBD and THC treat the most common type of lung cancer. Non-small lung carcinomas (NSCLC) represents 85% of all lung cancers.
Both canabinoid agonists (THC and CBD) alone, and especially in combination, significantly inhibited proliferation and invasiveness of Non-small cell lung carcinoma tumors (cell lines A549, H460, and H1792), in a dose-dependent manner.
Cannabinoids activate the specific G-protein coupled receptors CB1 and CB2. Although CB1 expression has been associated with the brain, and that of CB2 with the immune system, both receptors are expressed to some degree in other cells and organs (e.g., placenta, liver, endothelial cells, smooth muscle cells, and kidney).
Tumor samples with higher expression of cannabinoid receptors, especially CB1, showed increased survival time. Cannabidiol potentiated the effect of THC, and it is known to tame its psychoactive effects, making it a great combination for treatment.
